Latest Smallpox Stories
How well people are protected by the smallpox vaccine depends on more than the quality of the vaccination: individual genes can alter their response, Mayo Clinic research shows. The findings, gathered using sophisticated genomic screening, appear in today's online issue of the journal Genes and Immunity. "We were looking into the intercellular reactions that occur when vaccinated and unvaccinated persons are exposed to and infected with smallpox virus. We were able to use blood samples...
Connie K. Ho for redOrbit.com – Your Universe Online Researchers recently discovered how poxviruses, viruses that contain DNA, can change quickly; in particular, they have an “accordion-like” way of viral adaption to fight against host viral defenses. Poxviruses, which include smallpox, can lead to a number of diseases in both humans and animals. They are seen as harmful, as they can pass through the species barrier with low mutation rates. Recently, there has been renewed...
KVISTGAARD, Denmark, July 11, 2012 /PRNewswire/ -- - People with atopic dermatitis and HIV Now Eligible to Receive IMVAMUNE(R) in an Emergency Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. government has expanded the population that is eligible to receive its attenuated smallpox vaccine, IMVAMUNE(R), during an emergency. In the event of a public health emergency involving smallpox, the government may now authorize the use of IMVAMUNE(R) to protect...
ANNAPOLIS, Md., June 1, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) today announced that the Delaware Court of Chancery has issued its final judgment in the Company's litigation against SIGA Technologies. Upholding its September 22, 2011 ruling, the Court awarded PharmAthene 50% of the net profits over a period of ten years from all sales of SIGA's smallpox antiviral therapeutic, ST-246, and related products, after SIGA receives the first $40 million in net profits....
KVISTGARD, Denmark, May 22, 2012 /PRNewswire/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that the U.S. Department of Health and Human Services has supported the initiation of an expanded Phase 3 study of IMVAMUNE(R) smallpox vaccine. The government is stockpiling 20 million doses of IMVAMUNE(R) under a Project BioShield contract for use in a potential smallpox emergency. The company's procurement contract was modified, increasing the total value of the contract...
A new study by the World Health Organization (WHO) finds the number of deaths worldwide caused by measles has dropped about three-quarters over the past decade. While the number has universally dropped, most of the deaths occurred in India and Africa, where immunizations aren’t as accessible to children. According to health officials, nearly 9.6 million children were saved from measles in between 2000 and 2010, thanks to vaccination campaigns rolled out during this time. These campaigns...
Symposium on Smallpox Eradication and the Future of Global Health Featured in a Special Edition of the journal Vaccine WASHINGTON, April 24, 2012 /PRNewswire-USNewswire/ -- In a special edition of Vaccine released today, Sabin President, Dr. Peter Hotez, and Sabin Executive Vice President, Dr. Ciro de Quadros, share their insights on global health innovations and advancements since the eradication of smallpox was certified by the World Health Assembly in 1980. Their commentary is...
RESEARCH TRIANGLE PARK, N.C., April 3, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced presentations at two upcoming investor conferences in New York City. Timothy W. Trost, Chief Financial Officer, will present at the Needham Healthcare Conference on Wednesday, April 4, 2012 at 10:40 am ET at the Palace Hotel. Kenneth I. Moch, President and Chief Executive Officer, will present at the Future Leaders in the...
ANNAPOLIS, Md., March 8, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2011. "We were gratified by the favorable ruling from the Delaware Court of Chancery in September of 2011," remarked Eric I. Richman, President and Chief Executive Officer. "Under that ruling, the Court awarded PharmAthene the...
RESEARCH TRIANGLE PARK, N.C., March 5, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 3:00 pm ET at The Boston Marriott Copley Place in Boston, Massachusetts. Mr. Moch's presentation will include an update on the company's clinical pipeline, which includes...
Latest Smallpox Reference Libraries
Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It is well-known for its role in eradicating smallpox. It was the first human disease to to successfully be eradicated by science. The World Health Organization was the one who completed the endeavor. The vaccinia virus saw renewed interest in the early 21st century due to concerns about the smallpox virus being used as an agent for bioterrorism. They can be divided into four types:...
The Cowpox virus causes a skin disease known as cowpox. It is related to the vaccinia virus and gained its name because it spread by dairymaids touching the udders of infected cows. It manifests as red blisters. It is similar to smallpox although much milder and was actually the basis of the first smallpox vaccine. A person who recovers from cowpox is immune to smallpox. In 1980 the World Health Organization announced that smallpox was the first disease to be eradicated world wide by a...
